Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RCKTW - Rocket Pharmaceuticals Inc - Warrants (02/09/2026)


Previous close
0.0713
0   0%

Share volume: 8,044
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.07
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
33.33%
1 Month
14.29%
3 Months
-10.91%
6 Months
-69.23%
1 Year
-19.19%
2 Year
-73.33%
Key data
Stock price
$0.07
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.05 - $0.50
52 WEEK CHANGE
-$0.19
MARKET CAP 
1.716 B
YIELD 
N/A
SHARES OUTSTANDING 
91.014 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$54,129
AVERAGE 30 VOLUME 
$25,827
Company detail
CEO: Gaurav Shah
Region: US
Website: https://www.rocketpharma.com/
Employees: 205
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.

Recent news